Benzinga | Sep 23, 2020 08:31AM EDT

DURECT Corporation Announces First Patient Dosed In Phase 2 Safety And Efficacy Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury

CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The company plans to enroll approximately 80 patients in multiple study sites across the U.S.